asa glp 1 agonists Top GLP-1 Balance Weight Loss Efficacy, Safety PERIOPERATIVE GLP-1: ASA vs. GASTROENTEROLOGISTS

Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025

Block ML, Hong J-S

Ruiz-Tovar, J

In 2024 the Food and Drug Administration added cardiovascular risk as a reason to be prescribed the GLP-1 drug Wegovy, grounded in results from a major trial that showed fewer heart attacks, strokes, and cardiovascular deaths in adults with obesity or overweight and established heart disease

Abstract Background This study aimed to assess the prevalence of glucagon-like peptide-1 (GLP-1) receptor agonist use and interest in using medications for weight loss among adults ( 18 years) in Great Britain

Survodutide Dosing# Survodutide Phase 2 tested doses of 0.6, 2.4, 3.6, and 4.8 mg once weekly over 46 weeks